New Drug Approvals Archive
New Drug Approvals: July 2007
| July 3 | Tamiflu 30 mg and 45 mg Capsules Approved by U.S. Food and Drug Administration |
| July 6 | OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval to Use Cryoprecipitate from Talecris Biotherapeutics, Inc. in Its Manufacturing Process |
| July 9 | Exelon Patch (rivastigmine) Transdermal System Date of Approval: July 6, 2007 Company: Novartis Pharmaceuticals Corporation Treatment for Alzheimer's Disease Exelon Patch is a transdermal formulation of rivastigmine indicated for the treatment of mild to moderate Alzheimer's disease. Exelon Patch, the First and Only Skin Patch for the Treatment of Alzheimer's Disease, Receives First Worldwide Approval in US |
| July 9 | Scientists Locate First Common Bowel Cancer Gene |
| July 9 | World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland |
| July 20 | Nucryst Pharmaceuticals Receives FDA Clearance of Antimicrobial Barrier Topical Cream |
| July 25 | Anika Therapeutics Receives FDA Approval for Elevess Product |
| July 27 | Atralin Gel (tretinoin 0.05%) Gel Date of Approval: July 26, 2007 Company: Coria Laboratories, Ltd. Treatment for Acne Atralin Gel is a retinoid indicated for topical treatment of acne vulgaris. FDA Approves Atralin Gel for Topical Treatment of Acne Vulgaris |
| July 27 | Privigen (Immune Globulin Intravenous (Human)) 10% Liquid Date of Approval: July 26, 2007 Company: CSL Behring Treatment for Primary Immunodeficiency Syndrome, Idiopathic (Immune) Thrombocytopenic Purpura Privigen is a ready-to-use 10 percent liquid preparation of polyvalent human immunoglobulin indicated for the treatment of patients diagnosed with primary immunodeficiency (PI). Privigen is also indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding. CSL Behring Announces FDA Approval of Privigen-- First Proline-Stabilized 10 Percent Liquid IVIg |
| July 28 | CaloMist (cyanocobalamin) Nasal Spray Date of Approval: July 27, 2007 Company: Fleming & Company, Pharmaceuticals Treatment for Vitamin B12 Deficiency CaloMist is a nasal spray formulation of cyanocobalamin indicated for the maintenance of vitamin B12 concentrations in patients with vitamin B12 deficiency who have been normalized with intramuscular vitamin B12 therapy. FDA Approves CaloMist Nasal Spray for Vitamin B12 Deficiency |
| July 30 | EvaMist (estradiol) Transdermal Spray Date of Approval: July 27, 2007 Company: VIVUS, Inc. Treatment for Postmenopausal Symptoms EvaMist is an estradiol transdermal spray administered once daily for the treatment of vasomotor symptoms (hot flashes) associated with menopause. KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist |
New Drug Approvals Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec
